Clinical trial · Interventional
Women's Health Initiative (WHI)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To address cardiovascular disease, cancer, and osteoporosis, the most common causes of death, disability, and impaired quality of life in postmenopausal women. The three major components of the WHI are: a randomized controlled clinical trial of hormone replacement therapy (HRT), dietary modification (DM), and calcium/vitamin D supplementation (CaD); an observational study (OS); and a community prevention study (CPS). On October 1, 1997, administration of the WHI was transferred to the NHLBI where it is conducted as a consortium effort led by the NHLBI in cooperation with the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), the National Cancer Institute (NCI), and the National Institute on Aging (NIA).
Conditions
Conditions (9)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Bone Diseases | — | UNRESOLVED | — |
| Breast Neoplasms | Breast Neoplasm | ONTOLOGY_EXACT | 0.98 |
| Cardiovascular Diseases | — | UNRESOLVED | — |
| Colonic Neoplasms | Colon Neoplasm | ALIAS | 0.90 |
| Coronary Disease | — | UNRESOLVED | — |
| Heart Diseases | — | UNRESOLVED | — |
| Myocardial Ischemia | — | UNRESOLVED | — |
| Osteoporosis | — | UNRESOLVED | — |
| Postmenopause | — | UNRESOLVED | — |
Interventions
Interventions (8)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| calcium | Drug | — | UNRESOLVED |
| dietary supplements | Behavioral | — | UNRESOLVED |
| diet, fat-restricted | Behavioral | — | UNRESOLVED |
| estrogen replacement therapy | Drug | — | UNRESOLVED |
| estrogens | Drug | — | UNRESOLVED |
| hormone replacement therapy | Drug | — | UNRESOLVED |
| progestins | Drug | — | UNRESOLVED |
| vitamin D | Drug | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 50 Years
- Maximum age
- 79 Years
Show eligibility criteria text
Postmenopausal women ages 50 to 79.
References
Publications (1)
- Source
- PubMed (NLM)
- Dataset
- PubMed E-utilities
- Retrieved
- Sep 19, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
Margaret S Pichardo, Aaron K Aragaki, JoAnn E Manson et al. · Br J Cancer · Sep 16, 2026 · PMID 42749856 pubmed
- BACKGROUNDRossouw JE, Hurd S. The Women's Health Initiative: recruitment complete--looking back and looking forward. J Womens Health. 1999 Jan-Feb;8(1):3-5. doi: 10.1089/jwh.1999.8.3. No abstract available. PMID 10094073
- BACKGROUNDDesign of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Control Clin Trials. 1998 Feb;19(1):61-109. doi: 10.1016/s0197-2456(97)00078-0. PMID 9492970
- BACKGROUNDPatterson RE, Kristal AR, Tinker LF, Carter RA, Bolton MP, Agurs-Collins T. Measurement characteristics of the Women's Health Initiative food frequency questionnaire. Ann Epidemiol. 1999 Apr;9(3):178-87. doi: 10.1016/s1047-2797(98)00055-6.